2Q5

Renovaro Inc. (2Q5)

Market Open
3 Jul, 06:05
0. 24
0
0%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
0 Eps
0.24
Previous Close
Day Range
0.24 0.24
Year Range
0.24 1.72
Want to track 2Q5 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 76 days

Summary

2Q5 trading today higher at €0.24, an increase of 0% from yesterday's close, completing a monthly decrease of -7.6% or €0.02. Over the past 12 months, 2Q5 stock lost -69.96%.
2Q5 is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.09%, based on the last three reports. The next scheduled earnings report is due on Sep 29, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

2Q5 Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

Renovaro Inc. Dividends

2Q5 is not paying dividends to its shareholders.

Renovaro Inc. Earnings

29 Sep 2025 (In 2 months) Date
-
Cons. EPS
-
EPS
29 Sep 2025 (In 2 months) Date
-
Cons. EPS
-
EPS
13 May 2025 Date
-
Cons. EPS
0
EPS
12 Feb 2025 Date
-
Cons. EPS
-
EPS
12 Nov 2024 Date
-
Cons. EPS
-
EPS
2Q5 is not paying dividends to its shareholders.
29 Sep 2025 (In 2 months) Date
-
Cons. EPS
-
EPS
29 Sep 2025 (In 2 months) Date
-
Cons. EPS
-
EPS
13 May 2025 Date
-
Cons. EPS
0
EPS
12 Feb 2025 Date
-
Cons. EPS
-
EPS
12 Nov 2024 Date
-
Cons. EPS
-
EPS

Renovaro Inc. (2Q5) FAQ

What is the stock price today?

The current price is €0.24.

On which exchange is it traded?

Renovaro Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is 2Q5.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Sep 29, 2025.

Has Renovaro Inc. ever had a stock split?

No, there has never been a stock split.

Renovaro Inc. Profile

Biotechnology Industry
Healthcare Sector
David H. Weinstein CEO
XMUN Exchange
US29350E1047 ISIN
US Country
25 Employees
- Last Dividend
- Last Split
2 Feb 2015 IPO Date

Overview

Renovaro Inc. is a pioneering pre-clinical stage biotechnology entity focused on the development of novel pharmaceutical and biological therapies aimed at the treatment of critical illnesses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and various forms of cancer within the United States. Formerly known as Renovaro Biosciences Inc., the company underwent a rebranding in February 2024, marking a significant milestone in its evolution. Positioned strategically in Los Angeles, California, Renovaro Inc. collaborates closely with leading institutions such as the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross to leverage groundbreaking scientific research and development initiatives.

Products and Services

  • RENB-HV-01
  • An autologous HIV curative treatment in development that aims to provide a personalized approach to HIV eradication, leveraging the patient's own cells to combat the virus.

  • RENB-HV-12
  • A therapeutic HIV vaccine designed to elicit a robust immune response against the HIV virus, potentially altering the course of treatment for those living with this chronic condition.

  • RENB-HB-01
  • A gene therapy curative treatment targeting the hepatitis B virus, employing advanced gene-editing techniques to potentially cure HBV at the genetic level.

  • RENB-DC-11
  • An allogeneic dendritic cell therapeutic vaccine for pancreatic cancer, this product focuses on stimulating the immune system to recognize and destroy pancreatic cancer cells.

  • RENB-DC-12-XX
  • Similar to RENB-DC-11, this allogeneic dendritic cell therapeutic vaccine targets other solid tumors, offering hope for the treatment of various types of cancer with a single approach.

  • RENB-HV-21
  • A sophisticated treatment combining allogeneic natural killer (NK) and gamma delta T-cells to target HIV, this product represents an innovative approach to enhancing the body's natural defense mechanisms against the virus.

Contact Information

Address: 2080 Century Park East
Phone: 305 918 1980